Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial
May 16 2019 - 8:00AM
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical
company developing personalized cancer immunotherapies, today
announced the first clinical results from its ongoing Phase 1/2a
trial for GEN-009, the company’s lead neoantigen vaccine candidate.
Genocea employs its ATLAS™ platform for patient-specific neoantigen
selection, using each patient’s own T cells to identify the
neoantigens to which each patient mounts anti-tumor cytokine
responses.
“To date, we have analyzed full immune response data from three
patients following their priming series of three vaccinations and
have detected immune responses to 93% of the total administered
neoantigens, a response rate that would be best-in-class if seen
across the full vaccinated cohort,” said Tom Davis, M.D., Genocea’s
Chief Medical Officer. “We are studying a diverse group of patients
and, despite this variability, we are seeing consistently broad
immune responses, including ex vivo CD8+ T cell responses, which
have not previously been detected after monotherapy with a
neoantigen vaccine. We expect to present more detailed
immunogenicity and safety data from these and additional patients
at the upcoming meeting of the American Society of Clinical
Oncology (ASCO).”
ASCO POSTER SESSION: Developmental Immunotherapy and
Tumor ImmunobiologyPoster Board: #255 • *Abstract 2611
Title:
A
phase 1/2a study of GEN-009, a neoantigen vaccine based on
autologous peptide immune responsesPresenter:
Roger B. Cohen, M.D., University of Pennsylvania Perelman School of
MedicineDate:
Saturday, June 1, 8:00 AM - 11:00 AM Central TimeLocation:
Hall A
*Note: The abstract was submitted prior to the availability of
the immunogenicity data being reported today.
Conference Call and Webcast – June 3rd at 8:30 am
ETGenocea will host a conference call and webcast to
discuss the clinical results presented at ASCO at 8:30 am ET on
June 3, 2019. Interested participants may access the conference
call by dialing (844) 826-0619 (domestic) or (315) 625-6883
(international) and referring to conference ID number 9068006. To
join the live webcast, please visit the presentation page of the
investor relations section of the Genocea website at
https://ir.genocea.com/events-and-presentations. A webcast replay
of the conference call will be available on the Genocea website
beginning approximately two hours after the event and will be
archived for 90 days.
About Genocea Biosciences, Inc.Genocea is a
biopharmaceutical company developing personalized cancer
immunotherapies. Our unique ATLAS™ technology platform allows us to
identify immunotherapy targets based on each person’s tumor
antigen-specific T cell responses. Using ATLAS, we can both
optimize neoantigens for inclusion in our immunotherapies and
exclude so-called “inhibitory” antigens that appear to exert an
immunosuppressive effect on the patient. We are advancing
complementary programs built from ATLAS insights: GEN-009,
our neoantigen vaccine candidate for which we are conducting a
Phase 1/2a clinical trial across a variety of solid tumor types,
and GEN-011, our neoantigen-specific adoptive T cell therapy, for
which we intend to file an Investigational New Drug Application in
the first half of 2020. To learn more, please visit
www.genocea.com
Forward-Looking StatementsThis
press release includes forward-looking statements, including
statements relating to expectations of additional immunogenicity
and safety data from our Phase 1/2a clinical trial for GEN-009 and
intentions for filing an Investigational New Drug Application for
GEN-011, within the meaning of the Private Securities Litigation
Reform Act. Such forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements.
Genocea cautions that these forward-looking statements are subject
to numerous assumptions, risks and uncertainties that change over
time. Applicable risks and uncertainties include those identified
under the heading "Risk Factors" included in Genocea's Annual
Report on Form 10-K for the year ended December 31, 2018 and any
subsequent SEC filings. These forward-looking statements speak only
as of the date of this press release and Genocea assumes no duty to
update forward-looking statements, except as may be required by
law.
Contact:Jennifer
LaVin617-715-6687jennifer.lavin@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024